A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
Conditions
Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
Anhui Provincial Hospital, Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Capital Medical University Affiliated Beijing Ditan Hospital, Beijing, Beijing Municipality, China
The Fifth Medical Center of the PLA General Hospital, Beijing, Beijing Municipality, China
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
NanFang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China
Guangxi Zhuang Autonomous Region People's Hospital, Nanning, Guangxi, China
Harbin Medical University Affiliated Cancer Hospital, Harbin, Heilongjiang, China
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
The First Affiliated Hospital of Henan Medical University, Zhengzhou, Henan, China
Wells Prince Hospital of The Chinese University of Hong Kong, Hong Kong, Hong Kong, China
Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, China
Jiangxi Cancer Hospital, Nanchang, Jiangxi, China
Jilin University First Hospital, Changchun, Jilin, China
Liaoning Cancer Hospital, Shenyang, Liaoning, China
Shanghai Gaobo Tumor Hospital, Shanghai, Shanghai Municipality, China
Zhongshan Hospital Affiliated to Fudan University, Shanghai, Shanghai Municipality, China
Tianjin Medical University Cancer Hospital, Tianjin, Tianjin Municipality, China
Shao Yi Fu Hospital, Affiliated to the School of Medicine of Zhejiang University, Hangzhou, Zhejiang, China